On February 10, 2023 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 16/498,929, related to its B-cell activating immunotherapy PD1-Vaxx, currently in clinical development for non-small cell lung cancer (NSCLC) (Press release, Imugene, FEB 9, 2023, View Source [SID1234627010]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent titled "HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF" protects to 2038 the composition of matter and method of treatment in cancer of Imugene’s PD1-Vaxx for the generation of a therapeutic antibody response against the programmed death-1 (PD1) checkpoint target. Final preparations are in place for a clinical trial combining PD1-Vaxx in combination with atezolizumab (Tecentriq), an immune checkpoint inhibitor (ICI) targeting PD-L1, in patients NSCLC.
The objectives of the phase 1b trial, "An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab, in Adults with Non-Small Cell Lung Cancer," are to determine safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab as either first-line therapy in ICI treatment-naïve NSCLC patients or ICI pre-treated patients. The study will be conducted at sites in USA and Australia.
Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction and produce an anti-cancer effect similar to Tecentiqâ, Keytrudaâ, Opdivoâ and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.
Imugene MD & CEO Leslie Chong said: "It’s vital to our business that we continue locking in intellectual property protection across the portfolio of assets, and I am proud to continue to strengthen our IP. With the US being the largest healthcare market in the world, this is a particularly important patent to protect our PD1-Vaxx technology as we continue its development."